These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1672693)

  • 1. New concepts in Parkinson's disease.
    Sweeney PJ
    Hosp Pract (Off Ed); 1991 Apr; 26(4):84-94. PubMed ID: 1672693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurotransplantations: experimental studies].
    Dymecki J
    Neurol Neurochir Pol; 1993; 27(3):391-404. PubMed ID: 8232738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
    Mercuri NB; Calabresi P; Bernardi G
    Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
    [No Abstract]   [Full Text] [Related]  

  • 5. MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys.
    Lawrence MS; Redmond DE
    Pharmacol Biochem Behav; 1991 Apr; 38(4):869-74. PubMed ID: 1678527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplants in Parkinson's disease.
    Lindvall O
    Eur Neurol; 1991; 31 Suppl 1():17-27. PubMed ID: 1855521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell death in Parkinson's disease.
    Greenfield SA
    Essays Biochem; 1992; 27():103-18. PubMed ID: 1425598
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery.
    Kordower JH; Goetz CG; Freeman TB; Olanow CW
    Exp Neurol; 1997 Mar; 144(1):41-6. PubMed ID: 9126150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
    Jenner P
    J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):22-8. PubMed ID: 2666576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell death of dopamine neurons in aging and Parkinson's disease.
    Naoi M; Maruyama W
    Mech Ageing Dev; 1999 Nov; 111(2-3):175-88. PubMed ID: 10656535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP.
    Walters TL; Irwin I; Delfani K; Langston JW; Janson AM
    Exp Neurol; 1999 Mar; 156(1):62-70. PubMed ID: 10192777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
    Hurley MJ; Mash DC; Jenner P
    Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapeutic alternatives in Parkinson disease].
    García de Yébenes J; Fahn S
    Neurologia; 1987; 2(5):199-201. PubMed ID: 2908544
    [No Abstract]   [Full Text] [Related]  

  • 16. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 17. Possible mechanisms of action of adrenal transplants in Parkinson's disease.
    Drucker-Colín R; García-Hernández F; Mendoza-Ramírez JL; Pacheco-Cano MT; Komisaruk BR
    Prog Brain Res; 1990; 82():509-14. PubMed ID: 1963226
    [No Abstract]   [Full Text] [Related]  

  • 18. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging.
    Rinne UK
    Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular neuroanatomic mechanisms of Parkinson's disease: a proposed therapeutic approach.
    Gerfen CR; Engber TM
    Neurol Clin; 1992 May; 10(2):435-49. PubMed ID: 1350051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease.
    Kordower JH; Cochran E; Penn RD; Goetz CG
    Ann Neurol; 1991 Apr; 29(4):405-12. PubMed ID: 1681779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.